Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
23/09/2026 12:05
BRIEF-Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing Oruka Therapeutics Inc ORKA.O:
ORUKA THERAPEUTICS ANNOUNCES POSITIVE WEEK 28 DATA FOR ORKA-001 FROM THE ONGOING EVERLAST-A TRIAL SHOWING DEEPENING OF RESPONSES WITHOUT ADDITIONAL DOSING
ORUKA THERAPEUTICS - ORKA-001 MAINTAINS FAVORABLE SAFETY AND TOLERABILITY PROFILE THROUGH WEEK 28
ORUKA THERAPEUTICS - TWO SERIOUS ADVERSE EVENTS REPORTED, NEITHER DEEMED DRUG RELATED
ORUKA THERAPEUTICS - 16-WEEK EVERLAST-B DATA EXPECTED IN FOURTH QUARTER 2026
ORUKA THERAPEUTICS - 52-WEEK EVERLAST-A DATA EXPECTED IN DECEMBER 2026
Source text: ID:nGNX10yvmc
Further company coverage: ORKA.O
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary